Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
glaxosmithkline
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
fda
indiana blog main
indiana top stories
biogen
crispr
eli lilly
gene editing
gene therapy
messenger rna
roche
alzheimer's disease
amgen
amicus therapeutics
cancer immunotherapy
What
bio
crispr
5
×
roundup
5
×
ceo
new
acquisitions
albert
alliance
allogene
big
biggest
biopharma
bosley's
bosley’s
bourla
bridge
bristol
bucks
buy
calls
cancer
cas
changing
color
company
congress
congressional
crime
days
departure
diversity
drug
editas
executives
exit
feud
future
group
growing
guiding
Language
unknown
unset
Current search:
roundup
×
crispr
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More
